Biotech Hangover: Recent Earnings Feed Caution with No Near Term Catalysts
Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we posted that Risks were Rising...
Rayno Biopharmaceutical Portfolio Update: Buy and Hold is the Key…Update-2
Update 11/8/17 ...Per comments on Monday. Celgene (CELG) technicals are holding at $102-103 so we will add CELG to the Rayno Portfolio at a price of ~$102.5. The stock was battered on earnings news so we see good value and potential for long term growth. Forward PE is 11.74, Price/Sales is...
Rayno BioBeat #6: What Have I Missed After Two Weeks of Travel and Away From Trading Biotech Stocks?…Update 11/3
BioBeat Market Update...Technicals Firming Up 11/3/17 11am A lot of green screen today so time to nibble but I would prefer to pick stocks rather than play the ETF game. Recent trades we made are: sell XBI at $87, buy PFE at $35 and today buy CELG at $100. No change in our Biopharmaceutical...
Risks Rising for Rally: Political Rhetoric Tempers Bulls
Risks Rising for Healthcare Sector As Harsh Political Rhetoric Returns Trump returns to drug pricing attacks. Healthcare sector lags. Opioid crisis blames drug distribution companies for easy access. Sector on hold awaiting Q3 earnings: XLV down 0.44% today near its 52 week high. The early...
Small Cap Biotech Stocks Soar: How Long Will Rotation Last?
Speculation in Small Cap Biotech Picks Up-A Boon for Diligent Traders ETF Buying Is Driving All Small Cap and MicroCap Stocks Higher A Healthy Small Cap Rotation for Now: Reflation Trade ? Biotech stocks are rallying ahead of the expected strong seasonality in the November-January time frame. A...